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AbstractAnticoagulation with warfarin is characterized by a wide inter-individual variations in dose requirements and INR (International Normalised Ratio) stability, as there are evidences that warfarin response variability is associated with CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) and VKORC1 (Vitamin K epoxide reductase complex1) genetic polymorphisms. Carriers of CYP2C9*2 and VKORC11639G>A variant alleles are at greater risk of unstable anticoagulation therapy. Objectives: This retrospective case control study was directed to analyze the impact of genetic and non-genetic factors on warfarin therapy in Sudanese out-patients who were on long term warfarin therapy. Method: 118 Sudanese out-patients receiving warfarin treatment for at least six months, were interviewed for their non-genetic factors that included age, sex, indication for warfarin therapy, compliance, Vitamin K rich foods intake and concomitant drug therapy, in addition to their blood samples which were taken for DNA extraction and genotyping of CYP2C9*2 and VKORC11639G>A gene 
polymorphisms to study the genetic factors. INR stability % index was calculated, accordingly patients were classified into 2 groups, stable and unstable groups. Results: The frequencies of VKORC11639G>A alleles in Sudanese out-patients who were on long term warfarin therapy were 70.3% and 29.7% for the VKORC1/G and VKORC1/A alleles respectively. The frequencies of CYP2C9*2 alleles in Sudanese out-patients were 92.4% and 7.6% for CYP2C9*1 and CYP2C9*2 alleles respectively. Variables associated with low INR stability were VKCOR1/AA genotype (p-value = 0.028) and sex (p = 0.017). Variables that showed no association with INR stability were age (p-value = 0.259), compliance (p-value = 0.058). Vitamin K rich foods intake (p- value = 0.743), and mean stable warfarin dose (p-value = 0.439). Conclusion: Polymorphism in warfarin drug target gene VKORC1-11639G>A and sex are important elements of INR stability in Sudanese out- patients on long term warfarin therapy.
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1.  Introduction
1.1 Warfarin 
Warfarin is prescribed for patients who are at great 
jeopardy for creating a clot inside their blood vessels. 
Despite more than 50 years of experience using it and 
advances in the ability to monitor it, warfarin remains 
among the most problematic drugs to manage in clinical 
practice and a major cause of drug-induced morbidity 
and mortality. However, because they can be orally 
administered, warfarin remain the most frequently used 
agent when long-term anticoagulation therapy is needed1.
1.2 INR Stability
INR (International Normalized Ratio), is used to closely 
observe patients on warfarin treatment. The standard 
approximate range for the healthy persons is 0.8-1.2 and 
2-3 for people on warfarin treatment2. Outpatients always 
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come to the anticoagulation clinics with a non-consistent 
pattern of INR values, which are either higher or lower 
than the INR range specified for them, because it is quite 
effortful and hard to keep INR values within the specified 
range3. Therefore, a new indicator was defined in order 
to study warfarin’s anticoagulation long term therapy 
stability, which is the INR Stability %. INR stability % = 
100 x number of INRs within target range/total number of 
INR measurements4. A number of factors affect warfarin 
therapy, these factors include genetic factors and  non-
genetic factors of poor compliance, drug interactions, or 
vitamin K rich foods intake1.
2.  Problems with Warfarin
2.1 Non-genetic Factors
The number of reports of interactions between warfarin 
and drugs and foods are increasing. Although true 
mechanisms of drug interactions almost always remain 
unknown, many drugs were known to potentiate 
warfarin effect, which are inhibitors of CYP2C9 enzyme, 
such as amiodarone and fluconazole, while other drugs 
are CYP2C9 enzyme inducers such as rifampicin. The 
most difficult group of drugs are those that potentiate 
bleeding on their own, the risk of bleeding is then 
greater if they are taken with warfarin. Both vitamin 
K enriched and reduced diets affect INR stability, the 
enriched vitamin K diets  more rapidly than the reduced 
ones4. In5 considered interrelationship of vitamin K and 
responsiveness to warfarin in 50 patients, they found that 
the responsiveness to warfarin therapy was declined by 
high vitamin K enriched food intake. In6 studied patients 
on vitamin K supervised programme, they had achieved 
target INR more commonly than those on standard style 
of warfarin treatment, however, the clinical suitability of 
these findings for long term warfarin therapy requires 
more assessments.
2.2 Genetic Factors
2.2.1CYP2C9*2
Genes are identical in every population, but very limited 
numbers of genes are not similar in some people. Alleles 
constitute a gene with small discrepancy in the DNA 
bases sequence.
Single Nucleotide Polymorphisms (SNPs) are the most 
frequent and known type of genetic variations. SNPs come 
out commonly during lifetime, they arise approximately 
once every 300 nucleotides. When SNPs take place inside 
a gene, they lead to modifications in genes’ functions7. 
The wildtype allele CYP2C9*1*1 is directly correlated to 
normal warfarin metabolism activity, CYP2C9*2 is one 
of the most known CYP2C9 gene polymorphism, this 
polymorphism leads to reduction in warfarin metabolism. 
Therefore, warfarin doses are minimized by about one 
third when this type of gene variation is present8.
2.2.2. VKORC11639G>A
VKORC1 gene codes the vitamin K epoxide reductase 
enzyme complex 1, warfarin obstructs vitamin K actions 
and hence stops clotting factors formations. VKORC1 
1639G<A polymorphism is the most familiar gene 
polymorphism in populations of Asian and European 
origins9. Genotyping tests aim to improve the safety 
of warfarin dosing. Genetic variations of CYP2C9 
and VKORC1 can be identified by genotyping tests to 
identify patients with high risk of bleeding complications, 
meaning that determination of warfarin optimal dosing 
is best to be based on dosing algorithms which rely on 
both clinical features such as age, sex and weight along 
with genotypes profile. However, genotyping is a tool 
that may aid in selecting the correct dose of warfarin, but 
careful monitoring of INR is still required for optimal 
dose adjustments10,11. 
2.3 Ethnicity
There has been much concern recently about the concept 
the genetic testing. The great ethnic distinction in Sudan is 
a result of the early human African migrations which are 
not yet fully examined on the genetic level. Researchers at 
the Institute of Evolutionary Biology (IBE), have studied 
human genetic diversity in Sudan, they observed the 
populations that speak languages of the same linguistic 
family have a common shared genetic components, that 
is close genetic relationship between members of the 
same language family, demonstrating  that only linguistic 
evidence is relevant in drawing conclusions about 
Sudanese population classification12.
3. Objectives
The objective of our study is to analyse the genetic factors 
in terms of the prevalence of variant alleles of CYP2C9*2 
and VKORC1-1639G>A polymorphisms in Sudanese 
out-patients on long term warfarin therapy, to evaluate 
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their effects on the INR stability, in addition to the non-
genetic factors contribution.
4. Materials and Methods
The methodology for the study of the genetic and non-
genetic factors was performed through the following 
phases:
Phase 1
4.1Study Design
In this retrospective case-control study, Ethical clearance 
for the study procedure was acquired from the Sudanese 
Clinical Trials and Drug Research on Human and Animal 
Committee-National Medicines and Poisons Board. 
4.2 Patients
118 Sudanese out-patients attending the anti-coagulation 
clinic at the Sudan heart Centre–Khartoum–Sudan were 
selected. All Patients with a continuance anticoagulation 
treatment were recruited according to the inclusion 
criteria which included all patients being Sudanese 
with cardiovascular diseases who were on long term 
oral warfarin therapy and aged up to 75 years old. The 
exclusion criteria included patients who had a history of 
renal, hepatic, thyroid or malignancy diseases. To certify 
compliance with ongoing INR follow-up, patients needed 
to acquire one INR determination every four weeks for 
minimum of six months. 
4.3 Data Collection
The anticoagulation profile and a full warfarin dosing 
data were recalled from the patients’ hospital medical 
history documents which included INR values, dose of 
warfarin being administered, and the dose advised at each 
visit, and INR range. The tow variables which were to be 
calculated, the INR stability % and mean stable warfarin 
dose. The INR stability % was described as the percentage 
of the number of INR values within target range divided 
by the total number of INR measurements. INR stability % 
= Number of INR measurements within target range/ total 
no. of INR measurements x1004. The mean stable warfarin 
dose defined as the mean dose related to the stable INR 
measurements within target range. Mean stable warfarin 
dose = Number of warfarin stable doses /total number of 
warfarin doses2. Patients were then sorted out according 
to their INR stability % into two groups: Group1: Stable 
patients defined as patients who were having the highest 
percentages of INR stability %. i.e.,: An International 
Normalized Ratio (INR) greater than 2 but less than 3.5, 
4.0 or 4.5 according to their INR target range. Group 2: 
Unstable patients defined as patients who were having 
the lowest percentages of INR stability %. (Table 1.1 ) 
Demographic data and non-genetic factors included sex, 
age, ethnicity, indication for warfarin therapy, vitamin 
K rich foods intake, concurrent medications (type and 
number) and patient compliance (dose and schedule) were 
collected using a questionnaire. Venous blood samples (4 
ml) were collected and sent to the research laboratory 
and stored at -20 degrees preceding DNA extraction, to 
perform the genetic testing for both groups of patients to 
look at their genetic profiles and evaluate their relation to 
anticoagulation stability.
Table 1.1    Patients’ classification according to INR sta-
bility %
Patients’ 
Classification
INR
Stable group Higher percentages of INRs greater than 2 
and less than 3, 3.5 OR 4.
Unstable group Higher percentages of INRs less than 2 and 
greater than 3, 3.5 OR 4.
Phase 2
4.4 DNA Extraction
Genomic DNA was extracted from blood leukocytes using 
the QIAamp DNA blood Mini Kit (Quiagen), designed 
for rapid purification of genomic DNA.
Phase 3
4.5  Genotyping of CYP2C9*2, and VKORC1 
-1639G>A
Determination of the CYP2C9*2 and VKORC1-1639G>A 
genotypes was performed by polymerase chain reaction–
restriction fragment length polymorphism, (PCR-RFLP) 
technique. PCR for CYP2C9*2 and VKORC1-1639G>A 
was carried out using PCR technique of Maxime PCR 
PreMix Kit (i-Taq). Figures 1, 2. The primers sequences 
used for the protocols are given in  Table 1.2 below.
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Table 1.2    Primers used for CYP2C9*2, and VKORC1 
(-1639G>A) PCR protocol for DNA amplification
Gene Primer Sequence
CYP2C9 Forward:
5-TGCCTGTTTCAGCATCTGTC-3
Reverse:
5-CCCCTGAAATGTTTCCAAGA-3
VKORC1 Forward:
5-GCCAGCAGGAGAGGGAAATA-3
Reverse:
5-AGTTTGGACCTACAGGTGCCT-3
Figure 1.    PCR product of CYP2C9*2.
Lane M: DNA Marker.
Lanes 1, 2, 3, 4, 5, 6: PCR product of CYP2C9*2 (382bp). 
Lane 7: Heterozygous genotype of CYP2C9*2, three bands 
of fragments length of 382bp, 258bp and 129bp.
Figure 2.    PCR product of VKORC11639G<A.
Lane M: DNA Marker. Lanes 1, 2, 3, 4, 5, 6: PCR product 
of VKORC1-1639/GA (290 bp).
Phase 4
4.6  Restriction Fragment Length 
Polymorphism: RFLP
Phase 4.1 
4.6.1 Restriction Enzyme MsP1 
The MspI restriction enzyme was used to treat the 290 bp 
amplicon of VKORC1-1639G>A gene PCR product. First 
we prepared the restriction enzyme by dilution of the 
buffer provided with restriction enzyme by adding 1 ul of 
the buffer to 10 ul of distilled water, then we added 2,5 ul 
of the diluted buffer to 10 ul of PCR product, and 0.5 ul 
of restriction enzyme and 12 ul of distilled water making 
a final reaction volume of 25 ul. The PCR product was 
treated with the restriction enzyme Msp1 by adding the 
volumes above and left for incubation for 15 minutes at 
37 degrees, the 290-bp amplicon was cut into 2 restriction 
fragments of 167 and 121 bp , but in the case of the 
existence  of the A allele, this produced an amplicon that 
was insusceptible to  be cut by MspI restriction enzyme, 
Figure 3(a), 3(b).
Figure 3a.    VKORC1-1639G<A Polymorphism 
Representative Gel Electrophoresis:
Figure 3b. VKORC1-1639G>A polymorphism 
representative gel
Lane M: DNA Sizer. Lane 2, 3, 4: Heterozygous 
genotype of VKORC1, three bands of fragments length of 
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290bp, 169bp and 121 bp. Lane 5, 6, 7: Wild type VKORC1 
genotype, one band with a fragment length of 290 bp.
Lane M DNA sizer. Lane 5: Wild type genotype of 
VKORC1-1639/GA, two fragments length of 121 bp and 
169 bp.
4.6.2 Restriction enzyme Ava11 
To study the CYP2C9*2 allele, the PCR product of 
CYP2C9*2 was treated with the AvaII restriction enzyme. 
First we prepared  the AvaII restriction enzyme by dilution 
of the buffer provided with the restriction enzyme by 
adding 1 ul of the buffer to 10ul of distilled water, then 
2.5 ul of the diluted buffer was added to10 ul of PCR 
product, and 0.5 ul of restriction enzyme with 12 ul of 
distilled water making a final reaction volume of 25 ul. 
The PCR product was treated with the restriction enzyme 
AvaII by adding the volumes above and left for 15 minutes 
followed by incubation at 80 degrees for 20 minutes for 
inactivation of the enzyme, giving rise to two bands with 
lengths of 253 and 129  bp  for the wild-type allele. While 
the CYP2C9*2 allele was bearing no restriction by the 
AvaII restriction enzyme, producing one band with a 
length of 382 bp.
Figure 4. CYP2C9*2 Polymorphism Representative Gel
Lane M: DNA marker.
Lane 1: Homozygous mutant CYP2C9*2 genotype, 
one band of fragment length of 382bp.
Lanes 3, 4, 5: Wild type genotype of CYP2C9*2, two 
bands of 258 bp and 129bp.
5. Results 
Table 2.    Demographic and Basic Characteristics of 
Sudanese out-patients on long term warfarin therapy 
involved in the study: N = 118.
Age 48.0 +-16.4
No. of INR measurement 15.6+-7.0
INR stability % 33.9+-20.1
Mean stable warfarin dose 5.1+-2.4
Sex 77 Female (65.3%) 41Male (34.7%)
Indications
DVR (17) 14.5%
AF (35) 29.9%
MVR (30) 25.6%
AVR (22) 18.8%
CHD (1) 0.85%
PE (3) 2.6%
CVR (1) 0.85%
DCM (1) 0.85%
Stroke (1) 0.85%
DVT (1) 0.85%
Sinus thrombosis 1 (0.85%)
MI 2(1, 71%)
CVA 2 (1, 71%)
Low vit.K rich foods intake 41(34.75%)
Moderate vit.Krich foods intake 77(65.3%)
Correct compliance 104(89.7%)
Incorrect compliance 12(10.3%)
Target INR
2.0-3.0 51 (43.2%)
2.5-3.5 32 (27.1%)
3.0-4.0 29 (24.68%)
3.5-4.5 6 (5.0%)
Patient classification
Stable patients 60 (50.9%)
Unstable patients 58 (49.1%)
Data are represented as mean ± Std. OR number (percent).
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Figure 5. INR stability% versus patient’s classification of 
stable and unstable groups of Sudanese out-patients on long 
term warfarin therapy.
Obs.: No. of observations, N=118, P-value =0.0001.
Figure 6. Mean Stable warfarin dose.
P-value = 0.439, values are represented as mean.
Mean stable warfarin dose versus patients’ 
classification of stable and unstable groups of Sudanese 
out-patients on long term warfarin therapy N = 118.
Comparison of stable and unstable groups of Sudanese 
out-patients on long term warfarin therapy for Qualitative 
variables.
Compliance represented as frequencies of correct 
compliance and incorrect compliance as a function of 
patients’ classification of stable and unstable groups of 
Sudanese out- patients on long term warfarin therapy. 
Genetic tables:
89.90%
5.88% 4.20%
CYP2C9*1*1 CYP2C9*1*2 CYP2C9*2*2
CYP2C9*2 Genotype frequency
Figure 7. CYP2C9*2 genotypes frequencies among Sudanese 
out-patients on long term warfarin therapy: N=118. 
Data are represented as percent (%).
Figure 8. Alleles frequencies of CYP2C9*2 in Sudanese out- 
patients on long term warfarin therapy warfarin therapy: 
N=118.
CYP2C9*1: Wild type allele. 
CYP2C9*2: Variant allele.
92.40%
7.60%
CYP2C9*1 CYP2C9*2
Chart Title
N = 118, P-value = 0.713.Odds ratio = 1.5
Figure 9. Genotypes frequencies of CYP2C9*2 versus 
patients’ classification of stable and unstable groups of 
Sudanese out-patients on long term warfarin therapy.
Figure 10. VKORC11639G<A genotypes frequencies among 
Sudanese out- patients on long term warfarin therapy: 
N=118.
Data are represented as percent (%).
20.17%
67.23%
12.60%
VKORC1/GG VKORC1/GA VKORC1/AA
VKORC1  Genotype Frequency
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Figure 11. Alleles frequencies of VKORC11639G>A among 
Sudanese out-patients on long term warfarin therapy 
warfarin therapy: N=118.
Data are represented as percent%, G: Wild type allele , A: 
Variant allele .
70.30%
29.70%
G A
Frequency
Figure 12. Genotypes frequencies of VKORC1-1639G>A 
versus patients’ classification of stable and unstable groups 
of Sudanese out-patients on long term warfarin therapy.
N = 118, P-value = 0.024, Odds ratio = 4.9 (1-1) VKORC1 
wild type, (1-2) VKORC1 heterozygous, (2-2) VKORC1 
homozygous genotype.
Figure 13. Ethnicity versus patients’ classification of stable 
and unstable groups of Sudanese out-patients on long term 
warfarin therapy.
N=118, P-value = 0.910.
Table 3.    Carriers’ prevalence of CYP2C9*2 and 
VKORC1-1639G>A combinatorial profiles in Sudanese 
population involved in the study=118
VKORC1 CYP2C9*1*1 CYP2C9*1*2 CYP2V9*2*2 Total
GG 22 
(20.9%)
2 
(25%)
0 
(0.0%)
24 
(20.2%)
GA 72 
(68.5%)
3 
(37.5%)
5 
(100%)
80 
(67.2%)
AA 11 
(10.5%)
3 
(37.5%)
 
(0.0%)
14 
(11.8%)
Total 105 
(100%)
8 
(100%)
5 
(100%)
118 
(100%)
Data are represented as number (percent %) 
within CYP2C9*2 genotype classification. P-value = 
0.292. 22(20.9%) patients were wild-type homozygous 
CYP2C9*1*1 and VKORC1/GG. 0(0%) patients 
were homozygous mutant in both CYP2C9 and 
VKORC11639G<A genes simultaneously VKORC1/
GG: Wild type Genotype, VKORC1/GA: Heterozygous 
genotype, VKORC1AA: Homozygous mutant.
CYP2C9*1*1: Wild type homozygous genotype, 
CYP2C9*1*2: Heterozygous genotype, CYP2C9*2*2: 
Homozygous mutant genotype.
6. Discussion
VKORC1-1639G>A and CYP2C9*2 polymorphisms 
explain the variability of mean warfarin dose and hence 
stability among anticoagulation patients13. This was 
illustrated by the recent randomized clinical trials that 
was studying those two genes’ based warfarin dosing, 
the trials failed to prove a successful gene based dosing 
strategy which had actually performed worse than clinical 
dosing strategy in the 27% of patients who were of African 
ancestry. It is clear that warfarin dosing incorporates with 
the CYP2C9*2 and VKORC11639G>A single nucleotide 
polymorphisms, but do not adequately explain the 
variability in warfarin dosing in African populations14
Studies on haplotypes of VKORC1 gene showed that 
the highest haplotype diversity was observed in Sub-
Saharan Africans. The -1639 A allele (rs9923231) carried 
by haplotype H1, is the most frequent VKORC1 haplotype 
worldwide (49.7%)15.
Data on prevalence of VKORC11639G>A SNP among 
Sudanese populations are incomplete, but the available 
information concluded to that this SNP is the most 
frequent SNP among Sudanese, Kenyans and Egyptians 
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but not in West Africans. CYP2C9 is usually not seen in 
Africans or have low frequency in Africans. Also Sudanese 
population appear to have less CYP2C9*2 prevalence 
than other populations. Neither stability nor warfarin 
dose were associated with CYP2C9*2 variant allele16.
6.1 VKORC1-1639G>A
VKORC11636G>A polymorphism is associated with 
warfarin dose requirements among populations from 
African descent, of whom warfarin resistance is indicative 
although VKORC1 polymorphism showed highest 
diversity in allele frequency among different populations17.
Upon defining the population prevalence of 
VKORC1639G>A single nucleotide polymorphism, 
the genotype and allele frequencies are mentioned in 
Figures 9.10. The allele frequency for VKORC1 1639>G 
was reported to be highest in African American subjects 
(89%)18. This complies with our finding of the 70.3% 
VKORC11639>G allele frequency found in our Sudanese 
population.
On the other hand, the Minor Allele Frequency (MAF) 
of VKORC1 1639G>A allele was found to be 29.7%, 
shown as the A allele frequency19. The heterozygous 
VKORC1/GA genotype frequency has been found to be 
67.8%, which is a surprisingly high frequency among 
Sudanese population studied. This result is close to the 
results found by a study done on the southern Eastern 
European Romanians, in which it was found that 51.2% 
were carriers of VKORC1-1639/GA heterozygous 
genotype profile20.
Controversially, in a meta-analysis done by20, it was 
found that the frequency of wild type VKORC1-1639/
GG genotype was 58% in African populations. This 
VKORC1-1639G>A single nucleotide polymorphism had 
a significant influence in anticoagulation stability, as it has 
been seen. In this study, by comparing the VKORC1-1639/
AA homozygous mutant genotype carriers with the wild 
type VKORC1-1639/GG carriers versus stability, this gave 
an odds ratio of almost 5, meaning that individuals with 
mutant VKORC1-1639/AA genotype were 5 times more 
likely to be unstable unlike those of wild type genotype. 
This result was statistically significant, P value = 0.024. 
Figure 11. 
African ancestries are mainly noticed for their high 
warfarin dose requirements in contrast to Europeans and 
Asians21.
Several studies describe patients with warfarin 
resistance as mutation carriers in one copy of a gene that 
encodes VKORC1 enzyme, which results in an enzyme 
with a reduced ability to bind to warfarin, this reduction 
causes an incomplete warfarin resistance resulting in a 
higher dose of warfarin to be needed22.
 This is reflected by the mean warfarin dose among the 
unstable group of Sudanese populations studied, which 
comprised the group of the higher VKORC11639AA 
genotype, the dose which was 5.3±2.9 mg/day (37.1 mg/
week, range 57.4-16.8 mg/week), corresponds to the 
presence of the variant allele which was more frequent 
among the unstable group. This dose could be described 
as a high dose, since it complies with a study done 
on Egyptians who carry VKORC1 mutations showed 
high warfarin dose requirement of 57.1±29.4 mg/week 
versus those with normal VKORC1 genotype which was 
35.8±16.6 milligram per week23. 
 Also the generally high adjusted mean warfarin weekly 
dose range of 39 to 47 mg/week has been seen in Africans. 
The large scale population foundation of Africans 
compared to other races accounts for the complications 
in analysing individuals of an African origin21.
The results are clearly showing the high frequency of 
the heterozygous VKORC1- 1639GA genotype among 
all patients, constituting of the Afro-Asian racial group, 
with a frequency of 71%, in addition to 61% of the Nilo-
Saharans, and 50% of the Niger-Congos were carriers 
of VKORC1/GA heterozygous, but surprisingly without 
any VKORC1/AA homozygous mutant genotype for 
Niger-Congos. As the instability by VKORC1-1639G>A 
polymorphism is distinct by ancestral groups24. The allelic 
distribution of VKORC11639G>A showed a great degree 
of high prevalence across Sudanese patients different 
ethnical groups, being similar to the Indian populations 
different ethnicities, with VKORC1-1639G>A allele 
frequencies which were found to be as low as 6.5% and 
up to 70% 25. But, our results are quite different from the 
Chinese population whose genetic data had accounted 
for 90% of homozygous mutant VKORC1/AA genotype 
and only 10% of VKORC1/GA heterozygous genotype 
profile26.
6.2 CYP2C9*2
Allele frequency for CYP2C9*2 was 7.6% among Sudanese 
population for the Minor Allele Frequency (MAF) as 
it has been found in this study.  Figure 7. This result is 
unpredictably similar to those of Omani population, 
where minor allele frequency was markedly lower and 
was estimated at 7.4%27.
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The genotype frequencies are shown in Figure 
6, showing only 4.2% are carriers of CYP2C9 *2*2 
homozygous mutant genotype. The differences in genotype 
frequencies of CYP2C9 were not statistically different 
between stable and unstable groups, P-value = 0.713, and 
when comparing the CYP2C9*2*2 homozygous mutant 
genotype group with the CYP2C9*1*1 wild type genotype 
between stable and unstable groups, this comparison 
gave an odds ratio of 1.5, this shows that individuals 
with CYP2C9*2*2 mutant genotype are 1.5 times more 
likely to be unstable when compared to CYP2C9*1*1 
wild type genotype profile, this was not statistically 
significant, P-value = 0.713, as it can be seen in Figure 
8, since only 5 individuals have this genotype. The later 
result complies with a study done on Africans which did 
not detect an anticoagulation stability association with 
CYP2C9*2 variant, due to the low allele frequency as 92% 
were carriers of CYP2C9*1*1 wild type genotype28. The 
frequency of CYP2C9 polymorphism regarding ethnicity 
was unique in the genotype distribution among different 
Sudanese racial groups, having the highest frequency 
of 86.2% of CYP2C9*1*1 wild type allele among Afro-
Asians, showing the Nilo-Saharan and Niger-Congos 
having only this wildtype CYP2C9 *1*1 genotype profile 
with neither CYP2C9*1*2 heterozygous genotype nor 
CYP2C9*2*2 homozygous mutant genotype profiles.
From these results, given the smaller range of variant 
allele frequency for CYP2C9 to that of VKORC1, it is 
apparent that the association in warfarin therapy stability 
is larger for VKORC1 than for CYP2C929,30. By taking a 
general look at the ethnicity versus frequencies of both 
genes, we found that 22% of all Sudanese patients were 
without any of the variant alleles of both CYP2C9*2 
and VKORC1-1639G>A, that means having neither 
heterozygous nor homozygous mutant genotypes of 
the tow genes studied. Also 0% of all patients had 
mutations in both genes simultaneously. Table 3. But, the 
highest frequency was found for the VKORC11639/GA 
heterozygous genotype and the wild type CYP2C9*1*1 
genotype being 67.8% and 88.9% of all the patients 
respectively. This was explained in many studies that 
showed pharmacogenetics dosing incorporation of the 
two genes explained 40% of the instability in warfarin 
therapy among white ethnicities, but only 20% among 
Africans descents, this might be due to the reduced 
frequencies of these alleles as mentioned earlier14. 
6.3 Non-Genetic Factors
It appears there are no differences in warfarin 
anticoagulation stability in young versus elderly patients, 
in spite of age being a critical non-genetic factor for 
warfarin dose requirements31. In our study, the mean age 
among the stable patients was higher than in unstable 
patients (49.7+/-16.1, 46.3+/-16.8), however, age showed 
no significant difference statistically between stable 
and unstable groups, P-value = 0.259. The absence 
of significant association between age and warfarin 
anticoagulation stability indicates that age did not prevent 
patients, especially elderly ones, from maintaining their 
INRs within the recommended anticoagulation target 
INR ranges and gaining stability.
Figure 14. Frequency histograms of sex stratified according 
to patients’ classification of stable and unstable groups of 
Sudanese out- patients on long term warfarin therapy 
N=118.
P-value = 0.017, Blue panel = stable group, Green panel = 
unstable group.
Our results are confirmed by previous studies which 
showed warfarin’s INR stability is independently linked to 
age32. While other studies found a significant association 
between stability and age33. There are differences related to 
anticoagulants efficacy, especially among women, as it was 
found that female gender significantly spend more time 
outside the INR therapeutic range than men, as shown in a 
recently published study, 29% of women where below the 
INR therapeutic range versus 26% of men, by this putting 
them at a more risk of ischemic stroke34. In our study, INR 
values were of therapeutic stability in 42.9% of females 
among stable group versus 65% of males. Anticoagulation 
intensity was of a sub-therapeutic stability more among 
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females than males, (57.1% vs 34.2%) in unstable group 
respectively. The observed high instability among females, 
a result which was statistically significant, P-value = 0.017, 
Figure 3, can be documented by previous studies that 
showed anticoagulation variability was higher in females 
than in males35.
Our results demonstrate a higher frequency of stable 
patients who were on moderate rather than low vitamin 
K rich foods intake, 51.9% of stable patients were on 
moderate vitamin K rich foods intake versus 48.8% of 
stable patients were on low vitamin K rich foods intake, 
showing that stable INR could be achieved by taking 
moderate amounts of vitamin K rich foods. On the other 
hand, we found in this study, 51.2% versus 49.2% of 
unstable patients were on low and moderate vitamin K 
rich foods intake respectively. These results did not show 
a statistical difference between stable and unstable groups, 
P-value = 0.743, Figure 4. These results are convincing 
although the study was restricted by some factors which 
had faced all previous studies including the lack of an 
exact cut-off points of comprehensive enlightenment of 
the real content of vitamin K nutrient among Sudanese 
foods, which might be challenging to anticoagulation 
patients, taking into account, the study is a qualitative 
analysis of vitamin K rich foods, as utilization of vitamin 
K containing foods was considered low or moderate 
depending on the number of meals per week, without a 
real quantitative evaluation in ug/day.
Figure 15. Vitamin K rich foods intake.
P-value = 0.743, Blue panel = stable group, Green panel = 
unstable group 
 In this study, we found that patients with correct 
compliance were more frequent among stable group (75% 
versus 46.1%), while incorrect compliance frequency was 
higher among unstable group (53% versus 25%). This 
result indicates that stable patients were more compliant 
than unstable patients who were not compliant to warfarin 
therapy, but this result is without a statistically significant 
difference, P-value = 0.058, Figure 5. These findings are 
on line with a study that had found poor compliance with 
warfarin is a common risk factor for warfarin instability 
leading to serious complications36, 37.
Figure 16. Compliance.
N=118, P-value =0.058.
One of the reasons of the variation of warfarin 
dose and anticoagulation stability is the concomitant 
medications that could lead to drug-drug interactions. 
Therefore, each concurrent medication to be used 
within warfarin treatment should be checked for drug-
drug interactions reference. Even stable patients on 
concomitant medications should be tested at least once a 
month38. In this study, none of the observed concomitant 
medications had an association with warfarin stability. 
The statistically significant mean change in INR 
stability regarding stable and unstable groups, P-value 
= .0001, Figure 1, could be considered clinically due to 
the differences of genetic and non-genetic factors which 
were ruled out above. Although no statistical significant 
association was detected between most of those factors 
and stability, nor between stability and racial groups. 
As INR stability remains the reflection of the degree of 
anticoagulation status. Therefore, in Sudan it will remain 
an obligation to decide the most fitting mode of treatment 
for each patient individually, assuring that the most 
important aspect contributing to INR stability will remain 
the frequent monitoring, that is, at least once a month, if 
not once a week, to obtain a safe warfarin administration .
7. Conclusion
The high VKORC1-1639/GA heterogeneous genotype 
and VKORC1-1639/A allele frequencies noticed among 
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Sudanese patients, have a higher impact than CYP2C9*2 
in the stability of warfarin therapy. In conclusion, our 
final report suggests that among Sudanese patients, sex 
and VKORC1-1639/GA polymorphism had significant 
effects on INR stability. This study is one of the few 
studies which specifically looked into the genetic profiles 
of Sudanese population concerning CYP2C9*2 and 
VKORC1-1639G>A genes polymorphisms. However, 
further studies on these polymorphisms are essential for 
further confirmation. (29)
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